A Wiltshire-headquartered healthcare group has acquired a US scar treatment brand in a deal worth $19.4m (£14.8m).
Chippenham’s Alliance Pharma has bought ScarAway, and the rights to sell Kelo-cote in the retail consumer market in the US, from Perrigo Company Plc.
The UK business used cash from the group's existing financial resources to acquire both assets, it said.
